All In Biotech

Free tool

FAERS Monitor: Miudella

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218201 or its brand name (Miudella, Copper). Reports on generic versions are filed under their own applications.

Reports

737

Serious

493

67% of reports

Hospitalization

219

Death reported

40

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue75
  • off label use74
  • headache64
  • nausea64
  • pain62
  • diarrhoea61
  • drug ineffective52
  • weight decreased49
  • malaise43
  • abdominal pain40
  • anaemia36
  • dizziness36
  • dyspnoea36
  • constipation32
  • urinary tract infection29

Reports by year received

View as table
YearReports
20041
20054
20061
20073
20084
20096
20109
201114
201213
201321
201421
201532
201660
201723
201845
201956
202052
202163
202269
202362
202463
202567
202648

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,422 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anaemiaSignal365.43.9125
weight decreasedSignal495.03.8155
abdominal painSignal404.93.6122
urinary tract infectionSignal294.93.486
constipationSignal324.23.075
headacheSignal642.92.381
painSignal622.92.376
malaiseSignal432.82.149
fatigueSignal752.72.285
diarrhoeaSignal612.72.165
off label useSignal742.41.962
nauseaSignal642.31.848
dizzinessSignal362.11.519
dyspnoea361.81.313
drug ineffective521.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.